Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Positive initial clinical findings reported for first-generation GVAX vaccine for melanoma

Oct. 29, 1998

Positive efficacy and safety results reported for IDEC-Y2B8/Rituxan in NHL

Oct. 29, 1998

Japanese patent allowed for Maxamine technology

Oct. 22, 1998

Coulter announces positive investigational phase III results from Bexxar in NHL

Oct. 22, 1998

Endorex adds second site to phase II ImmTher trial

Oct. 16, 1998

Rituximab now available in Germany

Oct. 14, 1998

Antibody-based cancer product from AltaRex heading for phase I testing

Oct. 14, 1998

Coulter initiates expanded access program for Bexxar

Oct. 8, 1998

Patent issued for Neoprobe's RIGS/ACT anticancer technology

Oct. 7, 1998

Genentech's Herceptin given FDA approval

Sep. 28, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...